Firefly Neuroscience

What exists: 1) Intangible assets. Firefly holds an FDA 510(k) predicate for BNA software (2014) and sells an FDA‑cleared Evoke EEG System (2017), now in the FDA GUDID as commercially distributed. The company reports 23 issued U.S. patents with expirations from 2028 to 2037 and emphasizes a growing proprietary EEG/ERP dataset.

These create some IP and data differentiation but not exclusivity. 2) Switching costs. Subscription hardware with training and workflow integration adds friction, yet neurologists and behavioral health clinics can substitute with other EEG/qEEG vendors, limiting stickiness. 3) Network effects.

More scans may improve algorithms, but this is a data‑scale effect rather than a classic multi‑sided network; benefit accrues slowly and is not unique to Firefly. 4) Cost advantages. None evident versus established EEG hardware and software providers. 5) Efficient scale.

The niche is fragmented with multiple FDA‑cleared alternatives (for example VoxNeuro, BrainView, NeuroField), so efficient‑scale dynamics are weak. Component scores: Intangibles 45, Switching costs 30, Network effects 25, Cost advantages 20, Efficient scale 25; weighted to 31 overall.

Gross margins can be acceptable for software‑enabled devices, but payer behavior is the swing factor. Medicare contractor guidance around the eVox‑type panel historically pushed billing to unlisted code 95999 rather than stacking EEG and ERP codes, reflecting skepticism on panelling and clinical utility.

That undermines pricing leverage and provider ROI until consistent coverage exists. Competition from other FDA‑cleared EEG analytics further constrains price. We do not see latent pricing power akin to monopoly tollbooths.

Revenue is small and concentrated in early rollouts and projects. 2025 revenue was 1.142 million dollars and 1H26 revenue was 0.999 million dollars. Deferred revenue and leased equipment disclosures show some subscription visibility, but the base is modest.

Regulatory, payer and training variables add noise, and pharma services are inherently project‑based. We do not yet see tollbooth‑like predictability.

The company reported cash of 9.226 million dollars at June 30, 2026 after raising capital, with operating cash outflow of about 3.7 million dollars in 1H26 and an explicit going‑concern warning.

While there is little traditional debt outstanding post 2025 note conversion, reliance on equity financing and warrants is high, leaving limited resilience if capital markets tighten. Runway at the first‑half burn rate is roughly a year from June 30, 2026, barring changes in burn or new financing.

Management acquired Evoke Neuroscience in April 2025 to add commercial EEG hardware and accounts, which has lifted revenue, but funding has leaned on frequent equity raises, ATMs and warrant packages that are dilutive.

An S‑3 registered up to 22.5 million shares for resale tied to the March 2026 private placement, creating an overhang with limited direct proceeds to the company on resale by selling holders. While the Evoke deal is strategically sensible, the overall pattern is dilution‑heavy with no line of sight to self‑funding.

Leadership changed in 2025, with Greg Lipschitz elevated to CEO; the board includes executives with medtech and AI backgrounds.

Execution has delivered device deployments and revenue growth from a low base, yet persistent going‑concern language, reliance on equity capital and warrant structures, and limited operating scale temper our view of capital discipline.

Geographic exposure to Israel‑based R&D and talent also adds operational risk during regional hostilities, as disclosed.